Roche gifts blockbuster cancer drug to Galecto for new clinical partnership trial

Biotech company Galecto has partnered up with Roche, with the latter providing its cancer treatment Tecentriq free of charge for a mid-phase trial testing a combination of the blockbuster drug with one of three Galecto candidates. The deal is a significant cost saver for the Danish biotech company, which doesn't even have to surrender commercial rights for the potential combination treatment.
Hans Schambye, CEO at Galecto Biotech and chair at Danish Bio | Photo: Henriette Dan Bonde / PR
Hans Schambye, CEO at Galecto Biotech and chair at Danish Bio | Photo: Henriette Dan Bonde / PR
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN

The Danish-Swedish firm Galecto Biotech, which is spearheded by President and CEO Hans Schambye, has entered into a partnership with one of the giants of the pharmaceutical industry.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading